ENTITY
SMARTSCORE: 3/5

Assertio Holdings (ASRT US)

13
Analysis
Health CareUnited States
Assertio Holdings, Inc. operates as a pharmaceutical company. The Company offers oral suspension, suppositories, tablets, nasal spray, and capsules. Assertio Holdings serves clients in the United States.
more
03 Nov 2023 16:51

ASRT: Minimizing Indocin, PT $4

We are minimizing Indocin on a go forward basis. Rolvedon should continue to grow to help maintain profitability. Investor sentiment is not likely...

Logo
491 Views
Share
bullishHanmi Pharm
03 Oct 2023 15:50

Hanmi Pharm (128940 KS): Core Products Continue to Drive Sales; Pipeline Progress Raises Hope

​Hanmi Pharm is projected to clock record high revenue in 2023. The company's obesity drug is in phase 3 trial. Two rare disease drug candidates...

Logo
395 Views
Share
04 Aug 2023 18:22

ASRT: Generic Risk Extends Timeline, PT $6

ASRT disclosed there is generic competition for Indocin. There would be a few quarters before ASRT fully feels the competitive pressures from a...

Logo
538 Views
Share
10 May 2023 16:03

ASRT: Asserting a New Price Target, $10

Q1 results were better than expected and affirm our investment thesis of how ASRT could continue to generate free cash flow. SPPI, which ASRT is...

Logo
330 Views
Share
26 Apr 2023 19:04

ASRT: Rolling with Spectrum

ROLVEDON achieving sales materially higher than the current street consensus is the catalyst. The structure of the deal and the commentary from the...

Logo
303 Views
Share
x